Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 217

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 217
---
 the date they were prepared and neither Channel nor LNHC can give assurance that, had the LNHC Projections been prepared either as of the date of the Merger Agreement or as of the date of this information statement, similar estimates and assumptions would be used. The LNHC Projections do not take into account all of the possible financial and other effects of the Merger on LNHC, the effect on LNHC of any business or strategic decision or action that has been or will be taken as a result of the Merger Agreement having been executed, or the effect of any business or strategic decisions or actions that would likely have been taken if the Merger Agreement had not been executed, but which were instead altered, accelerated, postponed or not taken in anticipation of the Merger. Further, the LNHC Projections do not take into account the effect of any possible failure of the Merger to occur.

The LNHC Projections were not prepared with a view toward compliance with GAAP, published guidelines of the SEC or the guidelines established by the American Institute of Certified Public Accountants, or the “AICPA” for preparation or presentation of prospective financial information. Ernst & Young LLP has not audited, reviewed, examined, compiled or applied agreed-upon procedures with respect to the LNHC Projections and, accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance on such information or its achievability, and assumes no responsibility for, and disclaims any association with, the prospective financial information with respect thereto. The report of Ernst & Young LLP which is included in this information statement relates to historical financial information of LNHC, and such report does not extend to the LNHC Projections and should not be read to do so.

The LNHC Projections include financial measures, including net revenue, gross profit EBITDA and net income. These projections are based on a variety of sources including primary and secondary market research, scientific literature, clinical study data, and the experience of management and consultants. These financial measures should not be considered in isolation from, or as a substitute for, financial information presented as non-GAAP, and these financial measures may not be comparable to one another or to similarly titled measures used by other companies. We are not presenting a reconciliation of the financial measures included in the LNHC Projections to the relevant GAAP financial measures in this information statement and we undertake no obligation to update or otherwise revise or reconcile any of the LNHC Projections to reflect circumstances existing after the date the LNHC Pro